Core Viewpoint - Traws Pharma, Inc. has presented positive data for ratutrelvir, a main protease inhibitor, as a potential treatment for COVID-19, highlighting its advantages over current therapies, particularly the lack of need for co-administration with ritonavir [1][2][4]. Company Overview - Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases, including COVID-19 [9][10]. - The company aims to create safe antiviral agents with simple dosing regimens to address critical health threats [9]. Product Development - Ratutrelvir is designed to be an oral, small molecule Mpro (3CL protease) inhibitor that can be used without ritonavir, potentially avoiding drug-drug interactions and expanding patient eligibility [7][10]. - Preclinical and Phase 1 studies indicate that ratutrelvir maintains therapeutic blood levels significantly above the effective concentration (EC50) and does not require a metabolism inhibitor [5][7]. Clinical Data - Data from Phase 1 studies demonstrate excellent safety and tolerability for ratutrelvir, with a selected Phase 2 dosing regimen of 600 mg/day for 10 days showing promising pharmacokinetics [6][7]. - Laboratory studies confirm that ratutrelvir effectively suppresses replication of various SARS-CoV-2 strains, including Omicron variants, and maintains blood plasma levels above the EC90 [5][6]. Future Plans - Traws Pharma is preparing to engage with the FDA to discuss the path forward for ratutrelvir and plans to initiate Phase 2 studies [4][6]. - An Investor Event is scheduled for March 31, 2025, to present an overview of preclinical and human data on ratutrelvir [4][6].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 名额有限 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月21日，强生公司（Johnson & Johnson，纽约证券交易所代码：JNJ）宣布将在未来四年内投资超过550亿美元（约合4000亿人民币）用于其 在美国的制药和医疗器械业务。 此次投资比之前的周期增加了 25% ，将会增强强生公司在制造、研发和技术基础设施方面的实力。 强生公司表示，预计该投资将深化其在美国的经济影响 力。 # 投资详情 在宣布 最新投资消息时，强生公司刚刚表示会在北卡罗来纳州威尔逊新建一个价值 20亿美元、面积达50万平方英尺 的 生物制药生产工厂 ，支持癌症、自身 免疫性疾病和神经疾病下一代治疗药物的生产。 除了新建的北卡罗来纳州工厂外，强生公司还计划在其 创新药物和医疗器械业务 中新建 3个 先进制造工厂，并扩大几个现有场地，地点的细节尚未披露。 强生公司还表示，550亿美元的承诺将资助在 神经科学、机器人手术、肿瘤学、免疫学和心血管疾病 方面的重大研发投资。 目前，美国作为全球最大的医疗技术市场， 95% 的医 ...

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud affecting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Merck investors who were impacted by the company's misleading statements regarding expected revenue of $11 billion from Gardasil sales by 2030 [2] - Merck's optimistic forecasts were based on anticipated consumer activation and education efforts to drive demand for Gardasil, particularly in China [2] - On February 4, 2025, Merck announced it would not meet the $11 billion sales target for Gardasil by 2030, citing a need to halt shipments to China due to over-inflated inventories and lower-than-expected demand [2] - Following this announcement, Merck's stock price dropped from $99.79 to $90.74, a decline of over 9% in one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no costs or obligations for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). CONTACT US HERE: https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=137119&from=3 CLASS PERIOD: February 3, 2022 ...

OmniAb (OABI) Q4 2024 Earnings Call March 18, 2025 04:30 PM ET Company Participants Kurt Gustafson - CFOMatt Foehr - President & CEOPuneet Souda - Senior MD Conference Call Participants Joseph Pantginis - MD & Senior Healthcare AnalystMatt Hewitt - Senior Research AnalystSrikripa Devarakonda - AnalystNone - Analyst Operator Good afternoon and welcome to OmniAb Inc. Fourth Quarter and Full Year twenty twenty four Financial Results and Business Update Conference Call. At this time, all participants are in a l ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Merck (MRK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Merck currently has an average brokerage recommendation (ABR) of 1. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Merck & Co., Inc. securities between February 3, 2022, and February 3, 2025, of the April 14, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Merck securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 14, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that throughout the Class Period, Merck provided investors with optimistic revenue expectations of $11 billion from Gardasil sales by 2030 while concealing adverse facts about demand in China [4] - Defendants reportedly made materially false statements regarding the demand for Gardasil, leading to inflated inventory levels for its distributor, Zhifei [4]

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=134054&from=4 CLASS PERIOD: February 3, 2022 to Febru ...

Core Viewpoint - Investors in Merck & Co have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's business operations and inventory issues related to Gardasil in China [1][2]. Summary by Sections Lawsuit Details - The lawsuit claims that from February 3, 2022, to February 3, 2025, Merck failed to disclose critical information about the demand for Gardasil in China, leading to inflated inventory levels [2]. - The complaint asserts that the positive statements made by Merck regarding its business and prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses related to Merck are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for April 14, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

Mersana Therapeutics (MRSN) Q4 2024 Earnings Call March 03, 2025 08:00 AM ET Company Participants Jason Fredette - Senior Vice President of Investor Relations & Corporate CommunicationsMartin Huber - President & CEOBrian DeSchuytner - Senior VP, CFO & COOPaul Jeng - Vice President Conference Call Participants Yen-Der Li - Biotech Equity Research AnalystCharles Zhu - Managing Director, Senior Biotechnology Research AnalystAndy Hsieh - Research AnalystAsthika Goonewardene - AnalystNick Quartapella - Equity Re ...